TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Xoma ( (XOMA) ) has shared an update.
On December 5, 2025, XOMA Royalty Corporation completed its acquisition of Mural Oncology plc, following the Irish High Court’s sanctioning of the scheme of arrangement. Mural’s shareholders received $2.035 per share, and Mural’s shares were delisted from Nasdaq. This acquisition aligns with XOMA’s strategy to expand its portfolio of royalty rights in the biotech sector, potentially enhancing its market position and offering new opportunities for stakeholders.
The most recent analyst rating on (XOMA) stock is a Hold with a $35.00 price target. To see the full list of analyst forecasts on Xoma stock, see the XOMA Stock Forecast page.
Spark’s Take on XOMA Stock
According to Spark, TipRanks’ AI Analyst, XOMA is a Neutral.
Xoma’s overall stock score is primarily influenced by its financial performance, which shows strong profitability but is offset by high leverage and cash flow concerns. Technical analysis indicates mixed signals, with bearish momentum prevailing. The valuation suggests the stock may be overvalued, further impacting the score.
To see Spark’s full report on XOMA stock, click here.
More about Xoma
XOMA Royalty Corporation is a biotechnology royalty aggregator that focuses on acquiring potential future economics associated with pre-commercial and commercial therapeutic candidates licensed to pharmaceutical or biotechnology companies. The company provides non-dilutive, non-recourse funding to sellers, which can be used to advance internal drug candidates or for general corporate purposes.
Average Trading Volume: 52,793
Technical Sentiment Signal: Buy
Current Market Cap: $385.5M
For a thorough assessment of XOMA stock, go to TipRanks’ Stock Analysis page.